nach oben

Drugs

Erschienen in:

01.07.2018 | AdisInsight Report

Avatrombopag: First Global Approval

verfasst von: Matt Shirley

Erschienen in: Drugs | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Avatrombopag (Doptelet^®) is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders. In May 2018 avatrombopag received its first global approval, in the USA, for use in the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. A Marketing Authorization Application for use of avatrombopag in this indication was submitted to the EMA in April 2018. Clinical development of avatrombopag in the treatment of other thrombocytopenic disorders, including immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia, is ongoing. This article summarizes the milestones in the development of avatrombopag leading to this first approval for the treatment of thrombocytopenia in adult patients with CLD.

Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23.CrossRefPubMed

Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr Opin Hematol. 2012;19(5):392–8.CrossRefPubMed

Qureshi K, Patel S, Meillier A. The use of thrombopoietin receptor agonists for correction of thrombocytopenia prior to elective procedures in chronic liver diseases: review of current evidence. Int J Hepatol. 2016;2016:1802932.CrossRefPubMedPubMedCentral

Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–24.CrossRefPubMed

US FDA. Doptelet^® (avatrombopag) tablets: US prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf. Accessed 21 Jun 2018.

Terrault N, Chen Y-C, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018. https://doi.org/10.1053/j.gastro.2018.05.025.CrossRefPubMed

US FDA. FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure [media release]. 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608320.htm. Accessed 21 Jun 2018.

Dova Pharmaceuticals. Dova Pharmaceuticals announces FDA acceptance of the avatrombopag new drug application (NDA) with Priority Review [media release]. 2017. http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-acceptance-avatrombopag-new. Accessed 21 Jun 2018.

Dova Pharmaceuticals. Dova Pharmaceuticals reports first quarter 2018 operating and financial results [media release]. 2018. http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-reports-first-quarter-2018-operating-and. Accessed 21 Jun 2018.

10.

US FDA. Orphan drug designations and approvals. 2011. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=325110. Accessed 21 Jun 2018.

11.

Dova Pharmaceuticals. Dova Pharmaceuticals provides update on development strategy for avatrombopag in immune thrombocytopenic purpura (ITP) and chemotherapy-induced thrombocytopenia (CIT) [media release]. 2018. http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-provides-update-development-strategy. Accessed 21 Jun 2018.

12.

Eisai Co. Ltd. Eisai completes acquisition of MGI Pharma [media release]. 2008. https://www.eisai.com/news/news200803.html. Accessed 21 Jun 2018.

13.

Eisai Co. Ltd. Eisai completes acquisition of AkaRx, Inc. and continues development of AKR-501 for thrombocytopenia [media release]. 2010. https://www.eisai.com/news/news201001.html. Accessed 21 Jun 2018.

14.

Eisai Co. Ltd. Eisai’s U.S. subsidiary Eisai Inc. enters share purchase agreement concerning AkaRx Inc. in the U.S. [media release]. 2016. https://www.eisai.com/news/news201618.html. Accessed 21 Jun 2018.

15.

Dova Pharmaceuticals. Dova Pharmaceuticals signs exclusive distribution agreement with Fosun Pharma for mainland China and Hong Kong [media release]. 2018. http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-signs-exclusive-distribution-agreement. Accessed 21 Jun 2018.

16.

Terrault NA, Hassanein T, Howell CD, et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014;61(6):1253–9.CrossRefPubMed

17.

Frelinger AL, Koganov ES, Forde EE, et al. Avatrombopag, a novel thrombopoietin receptor agonist, increases platelet counts without increasing platelet activation in patients with thrombocytopenia due to chronic liver disease [abstract]. Blood. 2017;130(Suppl 1):290.

18.

Nomoto M, Pastino G, Rege B, et al. Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev. 2018;7(2):188–95.CrossRefPubMed

19.

Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84(5):952–60.CrossRefPubMed

20.

Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–94.CrossRefPubMed

21.

Jurczak W, Chojnowski K, Mayer J, et al. Avatrombopag, a novel oral thrombopoietin receptor agonist, demonstrates superiority to placebo for the treatment of chronic immune thrombocytopenic purpura in a phase 3, multicenter, randomized, double-blind, placebo-controlled trial [abstract]. Blood. 2017;130(Suppl 1):17.

22.

US FDA. Promacta^® (eltrombopag) tablets: US prescribing information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022291s019lbl.pdf. Accessed 21 Jun 2018.

Titel: Avatrombopag: First Global Approval
verfasst von: Matt Shirley
Publikationsdatum: 01.07.2018
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 11/2018
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-018-0949-8

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Avatrombopag: First Global Approval

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

New Developments in the Management of Cytomegalovirus Infection After Transplantation

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B

Vismodegib: A Review in Advanced Basal Cell Carcinoma

Regorafenib: A Review in Metastatic Colorectal Cancer

Erenumab: First Global Approval

Centrally Acting Agents for Obesity: Past, Present, and Future